Received Feb 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | — | — |
ended getting 3rd dose in 2/25; This non-serious case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose of Shingrix vaccine in March 2024) and Shingrix (received 2nd dose of Shingrix vaccine in May 2024). In FEB-2025, the patient received the 3rd dose of Shingrix. In FEB-2025, an unknown time after receiving Shingrix, the patient experienced extra dose administered (Verbatim: ended getting 3rd dose in 2/25). The outcome of the extra dose administered was unknown. Additional Information: GSK Receipt Date: 05-FEB-2025 The reporter reported that the patient received three doses of shingrix. Two doses two months apart in march 2024 and May 2024 patient was not sure if they got the second dose. Patient received 3rd dose in February 2025, after dose given after some research turned out patient got 2nd dose and wasn't reported, which led to extra dose administered. The Vaccine Administration Facility is the same as Primary Reporter.